MAP2K1 and cancer: Christopher M. Counter et al. suggested that combining a Cu chelator and MERK inhibitor may merit clinical consideration for the treatment of BRAF mutation-positive cancer and cancers developing resistance to MEK1/2 inhibitors 24, further demonstrating the potential of Cu in inducing cell differentiation.